HomeCompareMARUY vs ABBV

MARUY vs ABBV: Dividend Comparison 2026

MARUY yields 1.82% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MARUY wins by $42.82M in total portfolio value· pulled ahead in Year 4
10 years
MARUY
MARUY
● Live price
1.82%
Share price
$357.52
Annual div
$6.50
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.92M
Annual income
$38,823,958.22
Full MARUY calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — MARUY vs ABBV

📍 MARUY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMARUYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MARUY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MARUY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MARUY
Annual income on $10K today (after 15% tax)
$154.64/yr
After 10yr DRIP, annual income (after tax)
$33,000,364.49/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, MARUY beats the other by $32,978,497.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MARUY + ABBV for your $10,000?

MARUY: 50%ABBV: 50%
100% ABBV50/50100% MARUY
Portfolio after 10yr
$21.51M
Annual income
$19,424,841.97/yr
Blended yield
90.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MARUY
No analyst data
Altman Z
2.5
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MARUY buys
0
ABBV buys
0
No recent congressional trades found for MARUY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMARUYABBV
Forward yield1.82%3.12%
Annual dividend / share$6.50$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$42.92M$104.7K
Annual income after 10y$38,823,958.22$25,725.73
Total dividends collected$42.58M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MARUY vs ABBV ($10,000, DRIP)

YearMARUY PortfolioMARUY Income/yrABBV PortfolioABBV Income/yrGap
1$11,064$363.85$11,559$438.51$495.00ABBV
2$12,591$752.45$13,494$640.86$903.00ABBV
3$15,073$1,600.56$15,951$945.97$878.00ABBV
4← crossover$19,709$3,581.43$19,152$1,413.89+$557.00MARUY
5$29,842$8,753.48$23,443$2,146.38+$6.4KMARUY
6$56,705$24,773.69$29,391$3,321.96+$27.3KMARUY
7$148,663$87,988.42$37,948$5,265.87+$110.7KMARUY
8$590,243$431,174.03$50,795$8,596.74+$539.4KMARUY
9$3,831,395$3,199,835.16$71,034$14,549.41+$3.76MMARUY
10$42,923,551$38,823,958.22$104,715$25,725.73+$42.82MMARUY

MARUY vs ABBV: Complete Analysis 2026

MARUYStock

Marubeni Corporation engages in various business activities worldwide. The company trades in grains, feed ingredients, compound feeds, foods, agricultural and fishery products, and fresh and processed meat; and apparel, footwear, lifestyle, and textile and industrial materials. It also provides agri-inputs, contracting services for fertilizer application and crop protection products, technical services, crop protection product formulations, fertilizers, and oilseeds; ICT and real estate services; petrochemicals and plastics, salts and chlor-alkalis, life science products, electronic materials, and inorganic mineral resources and chemicals; and wood chips, biomass fuels, pulp and waste papers, paper, paperboards, sanitary, and building and construction materials, as well as wood products. In addition, the company explores for, develops, and produces oil and gas; trades in, distributes, and markets petroleum and LPG; develops uranium, nuclear fuel cycle, iron ore, coal, and copper mines, as well as related equipment sales and services; smelts and refines aluminum and magnesium; trades in iron ore, coking coal, non-ferrous metals, ingots and related products, and steel products; and leases temporary steel construction materials. Further, it offers engineering, procurement, and construction, as well as operation and maintenance services for railway systems, water, industrial plants, and waste-to-energy power plants; energy and transportation infrastructure, and water business; and manages infrastructure funds, as well as engages in the power generation, renewable energy, power service and retail, natural gas, hydrogen, ammonia, municipal solid waste, and thermal energy storage businesses. Additionally, it owns, purchases, operates, leases, sells, and charters aerospace and ship products; and sells, trades in, leases, finances, and services construction and industrial machinery, and mobility products. The company was founded in 1858 and is headquartered in Tokyo, Japan.

Full MARUY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MARUY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MARUY vs SCHDMARUY vs JEPIMARUY vs OMARUY vs KOMARUY vs MAINMARUY vs JNJMARUY vs MRKMARUY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.